JPMorgan Chase & Co. boosted its stake in shares of Castle Biosciences (NASDAQ:CSTL) by 643.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,542 shares of the company’s stock after purchasing an additional 10,855 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.07% of Castle Biosciences worth $374,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of CSTL. Bank of New York Mellon Corp boosted its position in shares of Castle Biosciences by 81.7% during the first quarter. Bank of New York Mellon Corp now owns 47,569 shares of the company’s stock worth $1,418,000 after buying an additional 21,383 shares during the period. State Street Corp increased its holdings in Castle Biosciences by 193.4% during the first quarter. State Street Corp now owns 149,979 shares of the company’s stock worth $4,471,000 after buying an additional 98,866 shares during the last quarter. BlackRock Inc. increased its holdings in Castle Biosciences by 64.3% during the first quarter. BlackRock Inc. now owns 715,195 shares of the company’s stock worth $21,320,000 after buying an additional 280,021 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Castle Biosciences during the first quarter worth about $255,000. Finally, UBS Group AG increased its holdings in Castle Biosciences by 28.7% during the first quarter. UBS Group AG now owns 6,683 shares of the company’s stock worth $199,000 after buying an additional 1,490 shares during the last quarter. Institutional investors own 42.74% of the company’s stock.
Shares of Castle Biosciences stock opened at $37.69 on Wednesday. Castle Biosciences has a 1 year low of $15.26 and a 1 year high of $44.53. The firm has a market cap of $604.25 million and a PE ratio of -43.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.64 and a quick ratio of 7.56. The company has a 50 day simple moving average of $37.90 and a two-hundred day simple moving average of $31.99.
A number of analysts recently issued reports on CSTL shares. SVB Leerink raised their price objective on shares of Castle Biosciences from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Robert W. Baird cut their target price on shares of Castle Biosciences from $38.00 to $35.00 and set an “outperform” rating for the company in a research report on Friday, March 27th. Canaccord Genuity increased their target price on shares of Castle Biosciences from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. BTIG Research increased their target price on shares of Castle Biosciences from $32.00 to $41.00 in a research report on Wednesday, March 11th. Finally, Zacks Investment Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Castle Biosciences presently has an average rating of “Buy” and an average price target of $39.00.
In other Castle Biosciences news, Director David S. Kabakoff sold 175,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $40.50, for a total value of $7,087,500.00. Following the completion of the transaction, the director now directly owns 212,178 shares in the company, valued at approximately $8,593,209. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie H. Anderson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.25, for a total value of $90,750.00. The disclosure for this sale can be found here. Insiders sold a total of 584,087 shares of company stock valued at $22,056,304 over the last 90 days. 39.70% of the stock is currently owned by corporate insiders.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Featured Article: No Load Funds
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.